Last reviewed · How we verify
Anticholinergic
At a glance
| Generic name | Anticholinergic |
|---|---|
| Also known as | Beta-agonists, Vesicare, BUP-4, Solifenacin, VESIcare |
| Sponsor | Medstar Health Research Institute |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Feasibility and Acceptability of a Collaborative Deprescribing Intervention to Reduce Anticholinergic Burden Among Hospitalised Older Patients (NA)
- TReating Incontinence for Underlying Mental and Physical Health (PHASE4)
- The Effect of the Anticholinergic Burden Following Elective Coronary Artery Surgery (PHASE4)
- Efficacy of Gabapentin Combined With Solifenacin for Non-neurogenic Overactive Bladder in Women (PHASE3)
- Study on the Effects and Mechanisms of Modified Ma Xing Shi Gan Decoction in Treating Acute Exacerbations of Chronic Obstructive Pulmonary Disease (NA)
- Anticholinergic Deprescription in Schizophrenia (PHASE4)
- Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder. (PHASE2)
- Stellate Ganglion Block Versus Oral Medication in Treatment of Palmar Hyperhidrosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anticholinergic CI brief — competitive landscape report
- Anticholinergic updates RSS · CI watch RSS
- Medstar Health Research Institute portfolio CI